Memorial Sloan Kettering Cancer Center Issues Statement on Third Quarter 2024 Financial Results

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its financial results for the first three quarters of 2024:

MSK's financial performance through the third quarter of 2024 demonstrate positive and consistent financial results, with an excess of operating revenue over expenses of $61.8 million and an operating cash flow margin of 5.2%. These operating results are attributed to effective expense management and an increase in patient activity.

Patient revenues increased by 13.7% compared to the first three quarters of 2023. Total operating expenses rose by 9.9% to support additional patient activity.

MSK's financial results are driven by a fiscal strategy grounded in expanding patient access, driving efficiencies, and managing expenses to help ensure continued financial stability.

For more information, please see instructions to access our financial disclosure report available at https://www.dacbond.com/ or https://www.mskcc.org/public-notices/financial-information.